NBIX Neurocrine Biosciences Earnings and EPS analysis

EPS in 2025 (TTM): $3.48

Last Report Period Date: Jun 30, 2025

As of August 2025, NBIX's current EPS stands at $3.48, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $3.4, which marks an increase compared to its EPS of $2.56 in 2023. NBIX reported an EPS of $1.09 for the quarterly report ending on Jun 30, 2025.

For 2024, Neurocrine Biosciences's EPS was $3.4, an increase of 32.8% from $2.56 in 2023. For the fiscal quarter that ended on Jun 30, 2025, the per-share earnings was $1.09, showing a 70.3% increase from the same quarter last year. For the twelve months ending June 2025, the EPS is $3.48. For the year 2023, the yearly earnings per share was $2.56, marking an increase of 59% from 2022.

During the last 12 months, Neurocrine Biosciences has seen an EPS growth of 70.3% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 53% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 53.4%.